Available in person at our Lincoln Park clinic or via telehealth anywhere in Illinois
2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated
Daily dosing is both a pro and a con
Liraglutide was approved in 2020 for use alongside lifestyle changes in pediatric patients 12 or older with a body weight over 60 kg (132 lbs.) and an initial BMI over 30
Why "fat burner" framing doesn't hold up An accurate fat-loss tool typically influences at least one of these directly: Appetite and satiety regulation Energy expenditure/thermogenesis Lipolysis and fat oxidation pathways Glucose regulation in a clinically meaningful way BPC-157 has not been established as reliably effective in humans for those categories of fat loss
doi: 10.1016/j.scienta.2018.10.007 28 DanevaA.GaoZ.Van DurmeM.NowackM
